Pacira BioSciences (NASDAQ:PCRX) Now Covered by Barclays

Barclays started coverage on shares of Pacira BioSciences (NASDAQ:PCRX) in a report published on Tuesday morning, MarketBeat.com reports. The brokerage issued an equal weight rating and a $27.00 target price on the stock.

A number of other equities analysts have also weighed in on PCRX. Wall Street Zen raised Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Truist Financial decreased their price target on shares of Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Friday, November 7th. HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a report on Monday, November 17th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Pacira BioSciences in a report on Monday, December 1st. Finally, Zacks Research raised shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.20.

Pacira BioSciences Price Performance

PCRX stock opened at $24.77 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 5.26 and a quick ratio of 3.78. The company’s 50-day moving average is $23.09 and its 200-day moving average is $24.13. The stock has a market capitalization of $1.07 billion, a PE ratio of 55.05 and a beta of 0.23. Pacira BioSciences has a 1 year low of $18.17 and a 1 year high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last issued its earnings results on Thursday, November 6th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. The business had revenue of $179.52 million during the quarter, compared to analyst estimates of $182.86 million. Pacira BioSciences had a return on equity of 12.82% and a net margin of 2.99%.The firm’s revenue was up 6.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.79 EPS. Equities research analysts expect that Pacira BioSciences will post 2.41 EPS for the current fiscal year.

Insider Activity

In other news, insider Jonathan Slonin sold 3,960 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $24.09, for a total value of $95,396.40. Following the completion of the sale, the insider owned 178,367 shares in the company, valued at $4,296,861.03. This represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pacira BioSciences

Institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its stake in Pacira BioSciences by 17.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,511 shares of the company’s stock valued at $84,000 after buying an additional 531 shares during the last quarter. US Bancorp DE boosted its stake in shares of Pacira BioSciences by 31.0% in the 1st quarter. US Bancorp DE now owns 2,270 shares of the company’s stock worth $56,000 after buying an additional 537 shares during the last quarter. Hantz Financial Services Inc. boosted its stake in shares of Pacira BioSciences by 175.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock worth $29,000 after buying an additional 721 shares during the last quarter. Inspire Investing LLC grew its holdings in shares of Pacira BioSciences by 5.1% in the third quarter. Inspire Investing LLC now owns 17,402 shares of the company’s stock valued at $448,000 after acquiring an additional 846 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Pacira BioSciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock valued at $677,000 after acquiring an additional 1,165 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.